Direct-Acting Antivirals and Host-Targeting Approaches against Enterovirus B Infections: Recent Advances

Enterovirus B (EV-B)-related diseases, which can be life threatening in high-risk populations,have been recognized as a serious health problem, but their clinical treatment is largely supportive,and no selective antivirals are available on the market. As their clinical relevance has become moreserious, efforts in the field of anti-EV-B inhibitors have greatly increased and many potential antiviralswith very high selectivity indexes and promising in vitro activities have been discovered. The scope ofthis review encompasses recent advances in the discovery of new compounds with anti-viral activityagainst EV-B, as well as further progress in repurposing drugs to treat these infections. Currentprogress and future perspectives in drug discovery against EV-Bs are briefly discussed and existinggaps are spotlighted.